search
Back to results

Pre-Hospital Use of Plasma for Traumatic Hemorrhage (PUPTH)

Primary Purpose

Shock, Hemorrhagic

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Plasma
Normal saline
Sponsored by
Virginia Commonwealth University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Shock, Hemorrhagic focused on measuring Trauma, Hemorrhage, Plasma, Shock, Polytrauma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Blunt or penetrating trauma,
  • Blood Pressure (BP) systolic <70 mmHg or BP 70-90 mmHg with Heart Rate (HR) > 108 Beats Per Minute (BPM),
  • Ongoing hemorrhage with unstable vital signs

Exclusion Criteria:

  • Wearing opt-out wrist band,
  • Wearing medical alert jewelry / bracelet, etc. indicating Jehovah Witness or similar with objections to blood transfusions,
  • Refusal to participate (by subject or LAR),
  • Communication barrier at the time of eliciting refusal (non-English speaking or non-Spanish speaking),
  • Not expected to survive transport to Virginia Commonwealth University Medical Center (VCUMC),
  • Documented Do Not Resuscitate (DNR) order found,
  • Cardiac arrest or Cardio-Pulmonary Resuscitation (CPR) prior to randomization
  • Penetrating head trauma,
  • Known / obvious pregnancy,
  • Prisoner,
  • Burns > 20% of body surface

Sites / Locations

  • Virginia Commonwealth University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Type A Thawed Plasma

Normal saline

Arm Description

Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders. An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained.

Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care

Outcomes

Primary Outcome Measures

Mortality
all cause mortality

Secondary Outcome Measures

Coagulation function (thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry)
thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry
Vital signs (blood pressure, pulse, temperature)
blood pressure, pulse, temperature
Blood product utilization (number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses)
number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses
Lipidomic profiles (arachidonic acid, eicosinoid expression, prostacyclin expression)
arachidonic acid, eicosinoid expression, prostacyclin expression
Blood biochemistry (pH, bicarbonate, lactate)
pH, bicarbonate, lactate
Hematology (Hemoglobin, hematocrit)
Hemoglobin, hematocrit
Hospital outcomes (number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections)
number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections

Full Information

First Posted
October 6, 2014
Last Updated
February 19, 2016
Sponsor
Virginia Commonwealth University
Collaborators
United States Department of Defense
search

1. Study Identification

Unique Protocol Identification Number
NCT02303964
Brief Title
Pre-Hospital Use of Plasma for Traumatic Hemorrhage
Acronym
PUPTH
Official Title
Pre-Hospital Use of Plasma for Traumatic Hemorrhage
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Withdrawn
Why Stopped
Low patient enrollment is the primary reason
Study Start Date
November 2014 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Virginia Commonwealth University
Collaborators
United States Department of Defense

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Type A Thawed Plasma (TP) will be compared in polytrauma patients who receive only Normal Saline (NS) (standard of care) before arrival at the hospital. The purpose of this study is to determine if prehospital administration of thawed plasma can reduce mortality of patients who have lost a large amount of blood due to their injuries, compared to those receiving standard of care.
Detailed Description
INVESTIGATIONAL PLAN This will be an open-label, non-blinded, randomized clinical trial to investigate mortality (30 days) and morbidity of Type A thawed Plasma (TP) versus NS infusion at earliest contact, administered by Emergency Medical Service (EMS) supervisors to subjects who have sustained severe Polytrauma / Major hemorrhage (PTr / MH). The total study is expected to last 2 years with 210 patients enrolled. The two EMS agencies involved in the study will each have one EMS supervisor quick-response vehicle (QRV) equipped with an approved, validated refrigeration unit for TP transport. EMS personnel trained in plasma administration and recognition of reactions may administer up to 2 units of TP to subjects approved for study enrollment. Blood samples for coagulation and lipid testing will be drawn prior to TP administration by EMS personnel,and repeated by hospital personnel at 30 minutes, 8 hours, and 24 hours post-injury. This study is approved for "Exception from Informed Consent" (EFIC). Once the patient has reached VCUMC and has been entered into the VCUMC health care system, the treating team will advise the Study Coordinator (SC) whether or not a subject is able to consent. As the plasma administration will occur in the field prior to arrival to VCUMC, the SC will make every effort possible to obtain consent from the subject or legally authorized representative (LAR) for continued study participation before the next intervention (8 hour blood specimen collection). The attempts to contact the LAR will be documented in detail. If a subject lacks the ability to provide his/her own consent by the end of day 30, the consent signed by the LAR will be the consent document in force at the subject's completion of the study and no further consent will be sought.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Shock, Hemorrhagic
Keywords
Trauma, Hemorrhage, Plasma, Shock, Polytrauma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Type A Thawed Plasma
Arm Type
Active Comparator
Arm Description
Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders. An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained.
Arm Title
Normal saline
Arm Type
Placebo Comparator
Arm Description
Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
Intervention Type
Biological
Intervention Name(s)
Plasma
Other Intervention Name(s)
Thawed Plasma
Intervention Description
Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
Intervention Type
Drug
Intervention Name(s)
Normal saline
Other Intervention Name(s)
0.9% Normal Saline
Intervention Description
Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
Primary Outcome Measure Information:
Title
Mortality
Description
all cause mortality
Time Frame
30 day
Secondary Outcome Measure Information:
Title
Coagulation function (thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry)
Description
thromboelastography, RoTEM, Hemodyne, fibrinogen, D-dimer, PFA-100, platelet count, flow cytometry
Time Frame
24 hours
Title
Vital signs (blood pressure, pulse, temperature)
Description
blood pressure, pulse, temperature
Time Frame
24 hours
Title
Blood product utilization (number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses)
Description
number of red blood cell units, number of plasma units, number of platelet units cryoprecipitate doses
Time Frame
30 days
Title
Lipidomic profiles (arachidonic acid, eicosinoid expression, prostacyclin expression)
Description
arachidonic acid, eicosinoid expression, prostacyclin expression
Time Frame
24 hours
Title
Blood biochemistry (pH, bicarbonate, lactate)
Description
pH, bicarbonate, lactate
Time Frame
24 hours
Title
Hematology (Hemoglobin, hematocrit)
Description
Hemoglobin, hematocrit
Time Frame
24 hours
Title
Hospital outcomes (number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections)
Description
number of cases of multi-system organ failure (MSOF), renal failure, length of hospital stay, length of ICU stay, number of days on a ventilator, number of surgeries, number of infections
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Blunt or penetrating trauma, Blood Pressure (BP) systolic <70 mmHg or BP 70-90 mmHg with Heart Rate (HR) > 108 Beats Per Minute (BPM), Ongoing hemorrhage with unstable vital signs Exclusion Criteria: Wearing opt-out wrist band, Wearing medical alert jewelry / bracelet, etc. indicating Jehovah Witness or similar with objections to blood transfusions, Refusal to participate (by subject or LAR), Communication barrier at the time of eliciting refusal (non-English speaking or non-Spanish speaking), Not expected to survive transport to Virginia Commonwealth University Medical Center (VCUMC), Documented Do Not Resuscitate (DNR) order found, Cardiac arrest or Cardio-Pulmonary Resuscitation (CPR) prior to randomization Penetrating head trauma, Known / obvious pregnancy, Prisoner, Burns > 20% of body surface
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruce D Spiess, MD, FAHA
Organizational Affiliation
VCU
Official's Role
Principal Investigator
Facility Information:
Facility Name
Virginia Commonwealth University
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is no data to share.
Citations:
PubMed Identifier
28183347
Citation
Reynolds PS, Michael MJ, Spiess BD. Application of Incident Command Structure to clinical trial management in the academic setting: principles and lessons learned. Trials. 2017 Feb 9;18(1):62. doi: 10.1186/s13063-016-1755-9.
Results Reference
derived
PubMed Identifier
26220293
Citation
Reynolds PS, Michael MJ, Cochran ED, Wegelin JA, Spiess BD. Prehospital use of plasma in traumatic hemorrhage (The PUPTH Trial): study protocol for a randomised controlled trial. Trials. 2015 Jul 30;16:321. doi: 10.1186/s13063-015-0844-5.
Results Reference
derived

Learn more about this trial

Pre-Hospital Use of Plasma for Traumatic Hemorrhage

We'll reach out to this number within 24 hrs